Skip to main content
Erschienen in: CEN Case Reports 3/2021

19.02.2021 | Case Report

The role of short-term, low dose intravenous ketamine infusion in Calciphylaxis

verfasst von: Shirin Ghanavatian, Dominika Lipowska James, Joshua Simon Sadolf

Erschienen in: CEN Case Reports | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Calciphylaxis is a small vessel vasculopathy causing subcutaneous ischemic necrosis. This condition is a recognized complication of end stage renal disease and is associated with severe pain. The mechanism of the pain generated by calciphylaxis is thought to be partly related to tissue ischemia, with a significant neuropathic component associated with neuronal hypoxic injury. The pain can be further exacerbated by the inflammatory process ensuing as a result of calciphylactic lesion infections which are commonly associated with this condition. Obtaining adequate pain relief is a challenging aspect of symptom control in calciphylaxis, and historically, patients suffering from calciphylaxis required high dose opioid medications to achieve satisfactory analgesia.
This case report presents a multimodal pain management approach utilizing low dose ketamine infusion in an opioid-tolerant patient suffering from severe calciphylaxis-related pain. Ketamine is an anesthetic agent well established for its efficacy in the management of neuropathic pain in opioid-tolerant patients, and has been shown to prevent opioid-induced hyperalgesia and decrease opioid requirements. Prior published data studying pain control in calciphylaxis have mainly focused on subcutaneous ketamine administration which as noted in the literature, can be associated with infusion site complications. To the best of our knowledge, this report is first of its kind to describe successful use of ketamine infusion in treatment of acute calciphylaxis-related pain.
Dose modification of ketamine is not required for patients with impaired renal function, and low dose intravenous ketamine infusion was associated with no reported adverse effects in our patient.
Literatur
1.
Zurück zum Zitat Gipstein RM, et al. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136(11):1273–80.CrossRef Gipstein RM, et al. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med. 1976;136(11):1273–80.CrossRef
2.
Zurück zum Zitat Oh DH, et al. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6 Pt 1):979–87.CrossRef Oh DH, et al. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6 Pt 1):979–87.CrossRef
3.
Zurück zum Zitat Polizzotto MN, et al. Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manage. 2006;32(2):186–90.CrossRef Polizzotto MN, et al. Symptomatic management of calciphylaxis: a case series and review of the literature. J Pain Symptom Manage. 2006;32(2):186–90.CrossRef
4.
Zurück zum Zitat Udomkarnjananun S, et al. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2019;4(2):231–44.CrossRef Udomkarnjananun S, et al. Treatment of calciphylaxis in CKD: a systematic review and meta-analysis. Kidney Int Rep. 2019;4(2):231–44.CrossRef
5.
Zurück zum Zitat King S, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–52.CrossRef King S, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–52.CrossRef
6.
Zurück zum Zitat Raina R, Krishnappa V, Gupta M. Management of pain in end-stage renal disease patients: short review. Hemodial Int. 2018;22(3):290–6.CrossRef Raina R, Krishnappa V, Gupta M. Management of pain in end-stage renal disease patients: short review. Hemodial Int. 2018;22(3):290–6.CrossRef
7.
Zurück zum Zitat Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251(4989):85–7.CrossRef Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991;251(4989):85–7.CrossRef
8.
Zurück zum Zitat Zhou HY, Chen SR, Pan HL. Targeting N-methyl-d-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4(3):379–88.CrossRef Zhou HY, Chen SR, Pan HL. Targeting N-methyl-d-aspartate receptors for treatment of neuropathic pain. Expert Rev Clin Pharmacol. 2011;4(3):379–88.CrossRef
9.
Zurück zum Zitat Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 1995;10(4):310–4.CrossRef Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 1995;10(4):310–4.CrossRef
10.
Zurück zum Zitat Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004;101(1):212–27.CrossRef Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004;101(1):212–27.CrossRef
11.
Zurück zum Zitat Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4(3):123–30.CrossRef Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008;4(3):123–30.CrossRef
12.
Zurück zum Zitat Aroni F, et al. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol. 2009;49(8):957–64.CrossRef Aroni F, et al. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol. 2009;49(8):957–64.CrossRef
13.
Zurück zum Zitat Capel MM, et al. Use of ketamine for ischemic pain in end-stage renal failure. J Pain Symptom Manage. 2009;35:232–4.CrossRef Capel MM, et al. Use of ketamine for ischemic pain in end-stage renal failure. J Pain Symptom Manage. 2009;35:232–4.CrossRef
14.
Zurück zum Zitat Kudoh A, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95(1):114–8.CrossRef Kudoh A, et al. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002;95(1):114–8.CrossRef
15.
Zurück zum Zitat Javery KB, et al. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996;43(3):212–5.CrossRef Javery KB, et al. Comparison of morphine and morphine with ketamine for postoperative analgesia. Can J Anaesth. 1996;43(3):212–5.CrossRef
16.
Zurück zum Zitat Trivedi S, et al. A comparative study of dexmedetomidine and midazolam in reducing delirium caused by ketamine. J Clin Diagn Res. 2016;10(8):UC01-4.PubMedPubMedCentral Trivedi S, et al. A comparative study of dexmedetomidine and midazolam in reducing delirium caused by ketamine. J Clin Diagn Res. 2016;10(8):UC01-4.PubMedPubMedCentral
17.
Zurück zum Zitat Orhurhu, VJ., et al. Ketamine Toxicity, in StatPearls. 2020: Treasure Island (FL). Orhurhu, VJ., et al. Ketamine Toxicity, in StatPearls. 2020: Treasure Island (FL).
18.
Zurück zum Zitat Fitzgibbon EJ, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage. 2002;23(2):165–70.CrossRef Fitzgibbon EJ, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage. 2002;23(2):165–70.CrossRef
19.
Zurück zum Zitat Elia N, Tramer MR. Ketamine and postoperative pain–a quantitative systematic review of randomised trials. Pain. 2005;113(1–2):61–70.CrossRef Elia N, Tramer MR. Ketamine and postoperative pain–a quantitative systematic review of randomised trials. Pain. 2005;113(1–2):61–70.CrossRef
20.
Zurück zum Zitat Honarmand A, Safavi M, Karaky H. Preincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomy. J Pain Res. 2012;5:1–6.PubMed Honarmand A, Safavi M, Karaky H. Preincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomy. J Pain Res. 2012;5:1–6.PubMed
21.
Zurück zum Zitat Maher J, et al. Balloon cell melanoma: a case report with polarized and non-polarized dermatoscopy and dermatopathology. Dermatol Pract Concept. 2014;4(1):69–73.PubMedPubMedCentral Maher J, et al. Balloon cell melanoma: a case report with polarized and non-polarized dermatoscopy and dermatopathology. Dermatol Pract Concept. 2014;4(1):69–73.PubMedPubMedCentral
22.
Zurück zum Zitat Mitchell AC, Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial. Pain. 2002;97(3):275–81.CrossRef Mitchell AC, Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischaemia: results of a double blind randomised controlled trial. Pain. 2002;97(3):275–81.CrossRef
Metadaten
Titel
The role of short-term, low dose intravenous ketamine infusion in Calciphylaxis
verfasst von
Shirin Ghanavatian
Dominika Lipowska James
Joshua Simon Sadolf
Publikationsdatum
19.02.2021
Verlag
Springer Singapore
Erschienen in
CEN Case Reports / Ausgabe 3/2021
Elektronische ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00557-8

Weitere Artikel der Ausgabe 3/2021

CEN Case Reports 3/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.